BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 31018945)

  • 21. Opposite Prognostic Impact of Single PTEN-loss and
    Lazaridis G; Kotoula V; Vrettou E; Kostopoulos I; Manousou K; Papadopoulou K; Giannoulatou E; Bobos M; Sotiropoulou M; Pentheroudakis G; Efstratiou I; Papoudou-Bai A; Psyrri A; Christodoulou C; Gogas H; Koutras A; Timotheadou E; Pectasides D; Zagouri F; Fountzilas G
    Cancer Genomics Proteomics; 2019; 16(3):195-206. PubMed ID: 31018950
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Circulating tumour DNA characterisation of invasive lobular carcinoma in patients with metastatic breast cancer.
    Davis AA; Gerratana L; Clifton K; Medford AJ; Velimirovic M; Hensing WL; Bucheit L; Shah AN; D'Amico P; Reduzzi C; Zhang Q; Dai CS; Denault EN; Bagegni NA; Opyrchal M; Ademuyiwa FO; Bose R; Gradishar WJ; Behdad A; Ma CX; Bardia A; Cristofanilli M
    EBioMedicine; 2022 Dec; 86():104316. PubMed ID: 36332363
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CCND1- and ERBB2-gene deregulation and PTEN mutation analyses in invasive lobular carcinoma of the breast.
    Mercapide J; Zhang SY; Fan X; Furió-Bacete V; Schneider J; López de la Osa I; Patchefsky AS; Klein-Szanto AJ; Castresana JS
    Mol Carcinog; 2002 Sep; 35(1):6-12. PubMed ID: 12203362
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CDH1 promoter hypermethylation and E-cadherin protein expression in infiltrating breast cancer.
    Caldeira JR; Prando EC; Quevedo FC; Neto FA; Rainho CA; Rogatto SR
    BMC Cancer; 2006 Mar; 6():48. PubMed ID: 16512896
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative proteomic analysis of ductal and lobular invasive breast carcinoma.
    Oliveira NC; Gomig TH; Milioli HH; Cordeiro F; Costa GG; Urban CA; Lima RS; Cavalli IJ; Ribeiro EM
    Genet Mol Res; 2016 Apr; 15(2):. PubMed ID: 27173185
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial.
    Llombart-Cussac A; Cortés J; Paré L; Galván P; Bermejo B; Martínez N; Vidal M; Pernas S; López R; Muñoz M; Nuciforo P; Morales S; Oliveira M; de la Peña L; Peláez A; Prat A
    Lancet Oncol; 2017 Apr; 18(4):545-554. PubMed ID: 28238593
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Utility of Oncotype DX Risk Assessment in Patients With Invasive Lobular Carcinoma.
    Tsai ML; Lillemoe TJ; Finkelstein MJ; Money JE; Susnik B; Grimm E; Kang SH; Swenson KK
    Clin Breast Cancer; 2016 Feb; 16(1):45-50. PubMed ID: 26385397
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PIK3CA and PTEN Genes Expressions in Breast Cancer.
    Alowiri NH; Hanafy SM; Haleem RA; Abdellatif A
    Asian Pac J Cancer Prev; 2019 Sep; 20(9):2841-2846. PubMed ID: 31554385
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular and morphologic distinctions between infiltrating ductal and lobular carcinoma of the breast.
    Yoder BJ; Wilkinson EJ; Massoll NA
    Breast J; 2007; 13(2):172-9. PubMed ID: 17319859
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Integration of somatic mutation, expression and functional data reveals potential driver genes predictive of breast cancer survival.
    Suo C; Hrydziuszko O; Lee D; Pramana S; Saputra D; Joshi H; Calza S; Pawitan Y
    Bioinformatics; 2015 Aug; 31(16):2607-13. PubMed ID: 25810432
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ESPL1 is a candidate oncogene of luminal B breast cancers.
    Finetti P; Guille A; Adelaide J; Birnbaum D; Chaffanet M; Bertucci F
    Breast Cancer Res Treat; 2014 Aug; 147(1):51-9. PubMed ID: 25086634
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential expression of miR-21, miR-125b and miR-191 in breast cancer tissue.
    Mar-Aguilar F; Luna-Aguirre CM; Moreno-Rocha JC; Araiza-Chávez J; Trevino V; Rodríguez-Padilla C; Reséndez-Pérez D
    Asia Pac J Clin Oncol; 2013 Mar; 9(1):53-9. PubMed ID: 22898264
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Frequent E-cadherin gene inactivation by loss of heterozygosity in pleomorphic lobular carcinoma of the breast.
    Palacios J; Sarrió D; García-Macias MC; Bryant B; Sobel ME; Merino MJ
    Mod Pathol; 2003 Jul; 16(7):674-8. PubMed ID: 12861063
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transcriptomic and genomic features of invasive lobular breast cancer.
    Desmedt C; Zoppoli G; Sotiriou C; Salgado R
    Semin Cancer Biol; 2017 Jun; 44():98-105. PubMed ID: 28400203
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Breast cancer: Role of IGF-1 and IGFBP-3 expression in prognostication.
    Raval A; Trivedi S
    Indian J Exp Biol; 2016 Oct; 54(10):619-629. PubMed ID: 30084561
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical outcome in pleomorphic lobular carcinoma: a case-control study with comparison to classic invasive lobular carcinoma.
    Narendra S; Jenkins SM; Khoor A; Nassar A
    Ann Diagn Pathol; 2015 Apr; 19(2):64-9. PubMed ID: 25682191
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic Role of PTEN Gene Expression and Length of Survival of Breast Cancer Patients in the North East of Iran.
    Golmohammadi R; Rakhshani MH; Moslem AR; Pejhan A
    Asian Pac J Cancer Prev; 2016; 17(S3):305-9. PubMed ID: 27165243
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Utilization of the 21-Gene Recurrence Score in a Diverse Breast Cancer Patient Population: Development of a Clinicopathologic Model to Predict High-Risk Scores and Response to Neoadjuvant Chemotherapy.
    Park KU; Chen Y; Chitale D; Choi S; Ali H; Nathanson SD; Bensenhaver J; Proctor E; Petersen L; Loutfi R; Simonds A; Kuklinski M; Doyle T; Dabak V; Cole K; Davis M; Newman L
    Ann Surg Oncol; 2018 Jul; 25(7):1921-1927. PubMed ID: 29679201
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Circulating microRNA-based screening tool for breast cancer.
    Frères P; Wenric S; Boukerroucha M; Fasquelle C; Thiry J; Bovy N; Struman I; Geurts P; Collignon J; Schroeder H; Kridelka F; Lifrange E; Jossa V; Bours V; Josse C; Jerusalem G
    Oncotarget; 2016 Feb; 7(5):5416-28. PubMed ID: 26734993
    [TBL] [Abstract][Full Text] [Related]  

  • 40. von Willebrand Factor Gene Expression in Primary Lower Grade Glioma: Mutually Co-Occurring Mutations in von Willebrand Factor, ATRX, and TP53.
    Lehrer S; Rheinstein PH; Green S; Rosenzweig KE
    Brain Tumor Res Treat; 2019 Apr; 7(1):33-38. PubMed ID: 31062529
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.